Impaired human leukocyte antigen (HLA) class I antigen processing and presentation due to homologous loss or down-regulation of B2M has also been found as a mechanism of acquired resistance to ICIs in lung cancer patients [94, 95]. This evidence concerns the gene B2M and lung cancer.